Journal article

+ 1 other files

Development and clinical validation of a blood test based on 29-gene expression for early detection of colorectal cancer

  • Ciarloni, Laura Novigenix SA, Biopôle IV, Epalinges, Switzerland
  • Ehrensberger, Sahar Hosseinian Novigenix SA, Biopôle IV, Epalinges, Switzerland
  • Imaizumi, Natsuko Novigenix SA, Biopôle IV, Epalinges, Switzerland
  • Monnier-Benoit, Sylvain Novigenix SA, Biopôle IV, Epalinges, Switzerland
  • Nichita, Cristina Service de Gastro-entérologie et d'Hépatologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
  • Myung, Seung-Jae Department of Internal Medicine, ASAN Medical Center, Seoul, Korea
  • Kim, Joo Sung Seoul National Univerisity, Korea
  • Song, Si Young Internal Medicine, Yonsei University College of Medicine, Korea
  • Kim, Tae Il Department of Internal Medicine, Yonsei University College of Medicine, Korea
  • Weg, Boudewijn van der Gastroenterologie, Spital Thun, Switzerland
  • Meier, Rémy Gastroenterology, Hepatology and Nutrition, Kantonsspital Liestal, Switzerland
  • Borovicka, Jan Abt.Gastroenterologie/Hepatologie, Kantonsspital St.Gallen, Switzerland
  • Beglinger, Christoph Department of Gastroenterology, University Hospital of Basel, Switzerland
  • Vallet, Cédric Service de Chirurgie, Ensemble Hospitalier de la Côte, Switzerland
  • Maerten, Philippe Internal Medicine, Clinique Cecil, Lausanne, Switzerland
  • Rüegg, Curzio Pathology, Department of Medicine, Faculty of Sciences, University of Fribourg, Switzerland
  • Dorta, Gian Service de Gastro-entérologie et d'Hépatologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Show more…
    28.04.2016
Published in:
  • Clinical Cancer Research. - 2016
English A blood test for colorectal cancer (CRC) screening is a valuable tool to for testing asymptomatic individuals and reducing CRC-related mortality. The objective of this study was to develop and validate a novel blood test able to differentiate patients with CRC and adenomatous polyps (AP) from individuals with a negative colonoscopy. Experimental Design: A case-control, multicenter clinical study was designed to collect blood samples from patients referred for colonoscopy or surgery. Predictive algorithms were developed on 75 controls, 61 large AP (LAP) {greater than or equal to}1cm, 45 CRC, and independently validated on 74 controls, 42 LAP, 52 CRC (23 Stages I-II) as well as on 245 cases including other colorectal findings and diseases other than CRC. The test is based on a 29-gene panel expressed in peripheral blood mononuclear cells alone or in combination with established plasma tumor markers. Results: The 29-gene algorithm detected CRC and LAP with a sensitivity of 79.5% and 55.4%, respectively, with 90.0% specificity. Combination with the protein tumor markers CEA and CYFRA21-2 resulted in a specificity increase (92.2%) with a sensitivity for CRC and LAP detection of 78.1% and 52.3%, respectively. Conclusions: We report the validation of a novel blood test, Colox®, for the detection of CRC and LAP based on a 29-gene panel and the CEA and CYFRA21-1 plasma biomarkers. The performance and convenience of this routine blood test provides physicians a useful tool to test average risk individuals unwilling to undergo upfront colonoscopy.
Faculty
Faculté des sciences et de médecine
Department
Médecine 3ème année
Language
  • English
Classification
Biology
License
License undefined
Identifiers
Persistent URL
https://folia.unifr.ch/unifr/documents/304891
Other files

Statistics

Document views: 14 File downloads:
  • rue_dcv.pdf: 1
  • rue_dcv_sm.pdf: 0